CSU IBC Meeting Minutes – APPROVED

Meeting title	CSU IBC Meeting June 2026
Date	June 17, 2026
Convened at	8:33am
Location	TMI Rm 222
Open or closed meeting (If closed, why?)	The meeting was closed briefly to discuss personal, proprietary, and/or security matters. The meeting was open the remainder of the time.
Review of prior meeting minutes	May 13, 2026 meeting minutes were approved as written.
Adjournment	9:21am
Recorded by	C. Johnson

Attendees

Check if Attending (Members):	**Check if Attending (Alternate Members):**
☒ Jessica Ayers, Animal expert	☐ Lon Kendall, Director LAR
☒ Donald Bade, Unaffiliated	
☐ Angela Bosco-Lauth, Associate Chair	
☐ Joshua Chan, Synthetic biology	
☒ Chaoping Chen, Chair	
☒ Jason Cummings, lab representative	
☐ Dan Frazen, Unaffiliated	
☒ Brendan Podell, Mycobacteria specialist	
☒ Ann Powers, Virology	
☒ Robyn Roberts, Plant expert	
☒ Joanie Ryan, Assistant Biosafety Director	☒ Rebecca Moritz, Biosafety Office Director*
☐ Tony Schountz, Virology	☒ Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 7 voting members; _8_ in attendance	*non-voting at this meeting
Non-Voting Members:	
☐	
☐ Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
☐ Michelle Ramey, Assistant Compliance Coord.	☒ Sonia Aleman Rivera, Assistant Biosafety Officer
☐ Nicole Marlenee, Biosecurity Specialist	☒ Kelly Kim, Assistant Biosafety Officer
☒ Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Mario Arango, OGC; Dell Rae Ciaravola, MarComm	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. **Review of May 13, 2026 IBC meeting minutes**
   The meeting minutes from May 13, 2026 were reviewed and approved as written.

2. **Agent/Project Review**

a. PI name/Lab	**Peebles Lab – Assigned Reviewers: Robyn, Chaoping, Joanie**
Project Number and Title	**26-023B: Generation of a biosensor to enhance olfaction v2**
Project Overview	This project aims to develop a protein based small molecule sensor to detect a small molecule such as theophylline or p-cresol produce the wintergreen scent (methyl salicylate). We will utilize protein engineering tools to create an allosteric switch out of S-adenosyl-L-methionine: salicylic acid carboxyl methyltransferase (SAMT) that can detect our small molecule and produce the wintergreen scent upon detection.
Planned Modifications	Generating rDNA plasmids for expressing proteins in E. coli
Agents used	• E. coli
NIH Guidelines Section	III-D-2
Proposed containment conditions (BSL, ABSL, etc.)	BSL1
Discussion	This is an experienced lab. 1. The IBC requests the E. coli AARF be amended to include the Nissele strain. 2. What is the source molecules for Yersinia enterocolitica. For example, will they be synthesized or isolated?
Verification of training	All training is up to date.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project with modifications described above (see Discussion).
Vote	The motion was unanimously approved.
b. PI name/Lab	**Harris Lab – Assigned Reviewers: Chaoping, Brendan, Joanie**
Project Number and Title	**26-025B: Modeling CHIP-Associated Myeloid Rewiring in DLBCL**
Project Overview	This project investigates how clonal hematopoiesis (CH)-associated myeloid cells influence the tumor microenvironment and therapeutic responses in diffuse large B-cell lymphoma (DLBCL). To accomplish this, genetically modified cells will be generated and used for in vitro experiments and xenograft studies to investigate the function of the mutation
Planned Modifications	Human-derived and canine-derived HSPCs will undergo ex vivo manipulation, including CRISPR/Cas9 gene editing and lentiviral transduction, to introduce CH-associated mutations
Agents used	• Replication-deficient lentiviral vector
NIH Guidelines Section	III-D-3, III-D-4, III-E-1
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2

Project Number and Title	**26-026B: Dissecting NRAS-Mediated Leukemic Stem Cell Persistence to Enable Durable AML Therapy**
Project Overview	This project investigates mechanisms of therapeutic resistance and leukemia persistence in acute myeloid leukemia (AML), with a particular focus on oncogenic RAS signaling pathways.
Planned Modifications	**NA**
Agents used	• NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	This is a new PI/lab. **For project 26-025B:** 1) Specify the institutional biosafety and animal care guidelines are, including disposition of animal carcasses 2) Describe/clarify human and canine trials. Is this referring to trials with cells lines? **For project 26-026B:** 1) Associate human materials with this project. 2) Specify how carcasses are disposed of and what the institutional biosafety and animal care procedures are.
Verification of training	All training is up to date.
Verification of facilities	The Lab is due for its Biosafety Outreach visit.
Motion	A motion was made to approve the projects with modifications described above (see Discussion).
Vote	The motion was unanimously approved.

3. Amendments requiring full IBC review

c. PI name/Lab	**Peebles Lab – Assigned Reviewers: Robyn, Chaoping, Joanie**
Project Number and Title	**15-092B: Expression of proteoglycans in Nicotiana benthamiana**
Project Overview	This project is to produce proteoglycans in Nicotianan benthamiana.
Planned Modifications	Express 7 proteins that come from human sequences that have been codon optimized for N. benthamiana.
Agents used	• Agrobacterium tumefaciens
NIH Guidelines Section	III-E-2
Proposed containment conditions (BSL, ABSL, etc.)	BSL1
Amendment request	Change the host plant from Nicotiana benthamiana to Wolffia australiana and Wolffia globosa
Discussion	This is an experienced lab.

	1. In the project title, the host should be changed from Nicotiana benthamiana to Wolffia australiana and Wolffia globosa (duckweeds). 2. Change Nb to Wa/Wg throughout. 3. Provide more information regarding cell cultures. Are these on plates (callus) or in liquid media? How are cell cultures being discarded? 4. For the duckweed species, will whole plants be generated or only cell cultures? 5. Will liquids be autoclave? Or inactivated with bleach? 6. Will the 7 proteins expressed in the original submission remain the same? 7. Are these stable transformants? How will duckweed by contain/handled to ensure it does not go down the drain? 8. Please describe decontamination methods for soil and any pots or containers.
Verification of training	All training is up to date.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project amendment with modifications described above (see Discussion).
Vote	The motion was unanimously approved.

4. New Business

None

5. Unfinished Business

a. **IBC Membership updates**

As a reminder, Angela will take over as the IBC Chair beginning July 1st; and Robyn will assume the role of Associate Chair. We will also have 3 new members, Marc Nishimura (plant expert), Carrie Satterwhite (unaffiliated), and Peter O'Brien (alternate unaffiliated).

b. **NIH Initiative to Modernize and Strengthen Biosafety Oversight** (https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy#tab2/)

No updates have been released.

6. Closed Session

Items to discuss

7. Reports

a. Coordinator's Report	1. Next IBC meeting: Wednesday, July 8, 2026
b. Biosafety Office Report	1. Inspections update: going well 2. Incident Reports: no incidents involving recombinant/synthetic nucleic acids to report

8. Public Comment

a. There was clarifying question regarding duckweed; it was answered by Dr. Roberts.
b. There was a question asking who the insurance underwriter for the bat facility is. As this question does not pertain to the meeting, the individual was instructed to submit their question via email.

9. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	a. **Akkina Lab** **Project:** Modeling stem-cell-based gene therapy for HIV using artificial thymic organoid system (26-016B); BSL2+. NIH Guidelines category non-exempt rDNA: III-D-1; III-D-3 b. **Foy Lab** **Project:** Exploiting probiotic delivery of a novel oral subunit vaccine against highly pathogenic avian influenza (26-021B); BSL2/ABSL2. NIH Guidelines category non-exempt rDNA: III-D-4 c. **Woerman Lab** **Project:** Investigating prion strain biology (23-039B); BSL2+/ABSL2+. NIH Guidelines category non-exempt rDNA: III-D-2; III-D-4